MRTX Mirati Therapeutics Inc.

78.45
+1.49  (+2%)
Previous Close 76.96
Open 77.27
Price To Book 6.53
Market Cap 3,082,780,379
Shares 39,296,117
Volume 396,476
Short Ratio
Av. Daily Volume 542,602
Stock charts supplied by TradingView

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 update at SITC November 2018 - 5/29 partial responses.
Mocetinostat and durvalumab
Non-small cell lung cancer (NSCLC)
Phase 2 Mechanism of Action data due 4Q 2019.
Sitravatinib and Nivolumab
Renal cell carcinoma (RCC)
Phase 3 interim analysis 4Q 2020, final data 4Q 2021.
Sitravatinib plus nivolumab
Non-small cell lung cancer (NSCLC)
Phase 1b initial data due 4Q 2019.
Sitravatinib and tislelizumab
Solid tumors
Phase 1/2 update due 4Q 2019. Possibly at AACR-NCI-EORTC October 26-29, 2019.
MRTX849
Solid tumors
Phase 2 initial data 4Q 2019.
Sitravatinib
Urothelial Carcinoma (Bladder)